Renaissance Technologies - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 102 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2021. The put-call ratio across all filers is 2.57 and the average weighting 0.1%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$70
-11.4%
59,700
+6.8%
0.00%
Q2 2023$79
-99.8%
55,900
+143.0%
0.00%
Q4 2020$40,000
-90.7%
23,000
-95.0%
0.00%
Q3 2020$432,000
+0.9%
460,806
-6.3%
0.00%
Q2 2020$428,000
+92.8%
491,700
+83.2%
0.00%
Q1 2020$222,000268,4000.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2021
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders